Literature DB >> 32239449

NLRP3 Depletion Fails to Mitigate Inflammation but Restores Diminished Phagocytosis in BV-2 Cells After In Vitro Hypoxia.

Isabelle Schölwer1, Pardes Habib2, Clara Voelz1, Leoni Rolfes3, Cordian Beyer1,4, Alexander Slowik5.   

Abstract

Post-hypoxic/ischemic neuroinflammation is selectively driven by sterile inflammation, which implies the interplay of brain-intrinsic immune cells with other neural cells and immigrated peripheral immune cells. The resultant inflammatory cascade evolves extra- and intracellular pathogen and danger-associated receptors. The latter interacts with multiprotein complexes termed inflammasomes. The NLRP3 inflammasome is one of the best-described inflammasomes. However, its impact on post-ischemic neuroinflammation and its role in neuroprotection after ischemic stroke are still under debate. Microglial cells are known to be the main source of neuroinflammation; hence, we depleted NLRP3 in BV-2 microglial cells using shRNA to investigate its role in IL-1β maturation and phagocytosis after hypoxia (oxygen-glucose-deprivation (OGD)). We also examined the expression profiles of other inflammasomes (NLRC4, AIM2, ASC) and caspase-1 activity after OGD. OGD triggered caspase-1 activity and increased IL-1β secretion in BV-2 cells with no alteration after NLRP3 depletion. The expression of the AIM2 inflammasome was significantly higher after OGD in NLRP3-depleted cells, whereas NLRC4 was unaltered in all groups. Interestingly, OGD induced a complete inactivation of phagocytic activity in wild-type cells, while in NLRP3-depleted BV-2, this inactivity was restored after hypoxia. Our findings indicate a minor role of NLRP3 in the inflammatory response after hypoxic/ischemic stimulus. However, NLRP3 seems to play a pivotal role in the regulation of post-ischemic phagocytosis. This might be a prerequisite for the putative neuroprotective effect.

Entities:  

Keywords:  AIM2; Hypoxia; Inflammasomes; NLRC4; NLRP3; Neuroinflammation; OGD; Phagocytosis

Mesh:

Substances:

Year:  2020        PMID: 32239449     DOI: 10.1007/s12035-020-01909-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  6 in total

1.  Erythropoietin Enhances Post-ischemic Migration and Phagocytosis and Alleviates the Activation of Inflammasomes in Human Microglial Cells.

Authors:  Eren Arik; Ole Heinisch; Michaela Bienert; Lara Gubeljak; Alexander Slowik; Arno Reich; Jörg B Schulz; Thomas Wilhelm; Michael Huber; Pardes Habib
Journal:  Front Cell Neurosci       Date:  2022-06-24       Impact factor: 6.147

2.  Mitofilin Mitigates Myocardial Damage in Acute Myocardial Infarction by Regulating Pyroptosis of Cardiomyocytes.

Authors:  Min Ma; Shi-Chu Liang; Kai-Yue Diao; Qin Wang; Yong He
Journal:  Front Cardiovasc Med       Date:  2022-05-02

3.  Gonadal Hormones E2 and P Mitigate Cerebral Ischemia-Induced Upregulation of the AIM2 and NLRC4 Inflammasomes in Rats.

Authors:  Pardes Habib; Julie Harms; Adib Zendedel; Cordian Beyer; Alexander Slowik
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

4.  Lactobacillus pentosus Alleviates Lipopolysaccharide-Induced Neuronal Pyroptosis via Promoting BIRC3-Mediated Inactivation of NLRC4.

Authors:  Ming Hu; Zhongying Shao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

5.  Aggregated Tau-PHF6 (VQIVYK) Potentiates NLRP3 Inflammasome Expression and Autophagy in Human Microglial Cells.

Authors:  Chinmaya Panda; Clara Voelz; Pardes Habib; Christian Mevissen; Thomas Pufe; Cordian Beyer; Sharad Gupta; Alexander Slowik
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

6.  GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3.

Authors:  Zhange Li; Honglin Xu; Xin Liu; Yang Hong; Han Lou; Heng Liu; Xue Bai; Lei Wang; Xia Li; Seth Mikaye Monayo; Justine Nyakango Mokembo; Nabanit Kumar Jha; Baofeng Yang; Yong Zhang
Journal:  Cell Death Dis       Date:  2020-10-25       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.